MS patients may receive less frequent rituximab infusions without increasing their chances of relapse or disease progression, ...

The following is a summary of “Rituximab combined with intravenous immunoglobulin in autoimmune diseases: a systematic review ...

A 2012 study of patients with low-tumor-burden follicular lymphoma showed that the 4-year freedom from treatment failure rate ...

For patients transitioning from rituximab to ravulizumab, meningococcal vaccination can be safely done within 6 months after ...

AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been recommended for approval in the European Union (EU) for the treatment of adult patients with previously ...

People with multiple sclerosis (MS) may receive less frequent infusions of rituximab without increasing their chances of relapse or disease progression, according to a real-world study from Norway.

EMA committee recommends approval of AstraZeneca’s Calquence plus chemoimmunotherapy to treat adult patients with mantle cell lymphoma: Cambridge, UK Tuesday, April 1, 2025, 17: ...

Learning from 2 decades of off-label rituximab use in systemic lupus erythematosus may point the way toward developing “new and improved” B-cell depleting agents for patients with the disease ...

Patient-reported outcomes measures in generalized myasthenia gravis (gMG) are more important than ever, for both those ...

Patients with early-onset atopic dermatitis, especially those with severe atopic dermatitis, are more likely to develop pediatric uveitis.

FDA approved AstraZeneca's Imfinzi regimen for muscle-invasive bladder cancer, while the EU backed Calquence combo for untreated mantle cell lymphoma.